Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that a hair serum containing Acanthus ebracteatus extract improved hair regrowth in men with androgenic alopecia, increasing hair count and density of anagen hairs over a 6-month period, with combination treatments showing early effectiveness.

Apremilast was not effective in treating moderate-to-severe alopecia areata.

New therapy helps treat hair loss.

This study in Mexican adolescents with severe alopecia areata reported that oral tofacitinib treatment resulted in hair growth and reduced alopecia severity without serious adverse effects.

In this observational study, researchers found that mini-pulse oral corticosteroids effectively reduced hair loss in alopecia areata patients who did not respond to topical therapies, though early-onset patients and those with hypothyroidism were less likely to benefit.

This paper presents the first reported case of Acute Localized Exanthematous Pustulosis linked to topical minoxidil use, suggesting a contact-induced hypersensitivity reaction as a potential mechanism.

This study found that AHCC significantly reduced alopecia caused by Ara-C in neonatal rats and improved liver function affected by 6-MP and MTX in mice.

Eosinophils are not a reliable marker for diagnosing alopecia areata.

This study found that combining intralesional PTX and corticosteroids may enhance treatment outcomes for alopecia areata, with PTX showing better long-term effects compared to corticosteroids alone.

This study evaluated the use of AI software SwissADME to compare Minoxidil and Sildenafil for alopecia treatment, finding Minoxidil to be more effective and safer, while highlighting limited potential for Sildenafil and emphasizing AI's role in optimizing drug development.

This study developed and validated a sensitive liquid chromatography–mass spectrometry method to measure aristolochic acid‐I in rat plasma, successfully applying it to pharmacokinetic research.

This study found that coadministration of tadalafil and finasteride improved lower urinary tract symptoms and erectile function in men with benign prostatic hyperplasia better than finasteride alone over 26 weeks.

This study reports promising preliminary trends in the safety and efficacy of a botanical drug candidate for pediatric alopecia areata, but conclusive results are not yet available.

This article discusses various potential health benefits and increasing global interest in astaxanthin but presents no new clinical results, though ongoing trials are exploring its effects on chronic diseases and other conditions.

This study in a nine-year-old boy from Lebanon identified a gene mutation (c.1066dup p.(Arg356Profs*16)) associated with a rare inborn error of immunity, characterized by craniosynostosis, jaundice, and several other symptoms, expanding the known genotypic and phenotypic spectrum of this condition.

This article discusses the effectiveness of adrenal cortex compounds E and F in treating connective tissue disorders like rheumatoid arthritis and lupus erythematosus, but it reports no new clinical results.

This study observed variable therapeutic responses in dogs with Alopecia X, with some showing complete hair regrowth while others did not, following similar treatments including orchiectomy and supplementation.

This study on alopecia areata meta-analyses highlights the risk of misleading results when ineffective, unsafe, or unapproved dosing regimens are included, recommending methodological safeguards to ensure accurate data interpretation and avoid inappropriate causal inferences.

In this study, a topical lotion containing Redensyl and Sepicontrol A5 demonstrated effectiveness for treating androgenetic alopecia over 24 weeks, with 73.1% of users seeing moderate improvement and notable increases in hair cycle ratios, alongside enhanced quality of life and satisfaction.

This study found that intralesional pentoxifylline injections were effective for localized alopecia areata, with the best results observed when combined with triamcinolone acetonide.

In this study, the researchers developed an optimal emulgel formulation for treating androgenic alopecia, determining that a base with 0.3% Carbomer Ultraz 10, 0.1% potassium sorbate, and 0.2% triethanolamine offered the best properties for drug release, application compliance, safety, and stability.

This article compiles internet forum posts discussing differences between brand-name and generic finasteride pills, but it presents no new clinical findings.

This study concluded that niosomes could effectively serve as stable carriers for topical aminexil delivery, showing promising stability and a slow, biphasic release profile in laboratory settings.

This source reports that clascoterone cream has been approved in the U.S. for treating acne vulgaris in patients aged 12 and older, suggesting it works by competing with dihydrotestosterone at androgen receptors to mitigate acne's effects.

This case study highlights a patient with alopecia areata who also has eosinophilic esophagitis, suggesting it may be considered an atopic disease and a potential trigger for alopecia areata in affected patients.

This study identified LY191704 as a specific noncompetitive inhibitor of human 5 alpha-reductase type 1, which may be useful in treating endocrine disorders related to DHT overproduction.

This study found that the methanolic heartwood extract of Avicennia marina significantly inhibits 5α-reductase type 1, reducing 5α-DHT production by 52% in a cell-based assay with human hair dermal papilla cells.